Format

Send to

Choose Destination
Semin Arthritis Rheum. 2015 Aug;45(1):55-9. doi: 10.1016/j.semarthrit.2015.02.008. Epub 2015 Feb 20.

Mycophenolate mofetil in primary central nervous system vasculitis.

Author information

1
Unitá Operativa di Reumatologia, Azienda Ospedaliera-IRCCS di Reggio Emilia, Reggio Emilia, Italy. Electronic address: salvarani.carlo@asmn.re.it.
2
Department of Neurology, Mayo Clinic, Rochester, MN.
3
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
4
Department of Radiology, Mayo Clinic, Rochester, MN.
5
Division of Anatomic Pathology, Mayo Clinic, Rochester, MN.
6
Unitá Operativa di Reumatologia, Azienda Ospedaliera-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
7
Division of Rheumatology, Mayo Clinic, Rochester, MN.

Abstract

OBJECTIVE:

To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV).

METHODS:

We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies.

RESULTS:

We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia.

CONCLUSION:

MMF seems to be an effective and safe therapy for adult PCNSV.

KEYWORDS:

Mycophenolate mofetil; PCNSV; Therapy; Vasculitis

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center